101 related articles for article (PubMed ID: 35436877)
1. Human papillomavirus vaccination at the national and provincial levels in China: a cost-effectiveness analysis using the PRIME model.
Zhou L; Gu B; Wang J; Liu G; Zhang X
BMC Public Health; 2022 Apr; 22(1):777. PubMed ID: 35436877
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of human papillomavirus vaccines for the prevention of cervical cancer in India.
Arora S; Tuffaha H
Asia Pac J Clin Oncol; 2024 Feb; 20(1):55-62. PubMed ID: 37132538
[TBL] [Abstract][Full Text] [Related]
3. Potential health impact and cost-effectiveness of bivalent human papillomavirus (HPV) vaccination in Afghanistan.
Anwari P; Debellut F; Vodicka E; Clark A; Farewar F; Zhwak ZA; Nazary D; Pecenka C; Scott LaMontagne D; Safi N
Vaccine; 2020 Feb; 38(6):1352-1362. PubMed ID: 31870571
[TBL] [Abstract][Full Text] [Related]
4. Modeling the epidemiological impact and cost-effectiveness of a combined schoolgirl HPV vaccination and cervical cancer screening program among Chinese women.
Ma X; Harripersaud K; Smith K; Fairley CK; Zou H; Zou Z; Wang Y; Zhuang G; Zhang L
Hum Vaccin Immunother; 2021 Apr; 17(4):1073-1082. PubMed ID: 33269990
[TBL] [Abstract][Full Text] [Related]
5. National and provincial impact and cost-effectiveness of Haemophilus influenzae type b conjugate vaccine in China: a modeling analysis.
Zhang H; Garcia C; Yu W; Knoll MD; Lai X; Xu T; Jing R; Qin Y; Yin Z; Wahl B; Fang H
BMC Med; 2021 Aug; 19(1):181. PubMed ID: 34376214
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of the cost of human papilloma virus (HPV) vaccine delivery in Zambia.
Simuyemba MC; Chama-Chiliba CM; Chompolola A; Sinyangwe A; Bchir A; Asiimwe G; Chibwesha C; Masiye F
BMC Infect Dis; 2024 Apr; 24(1):369. PubMed ID: 38565994
[TBL] [Abstract][Full Text] [Related]
7. Health and economic effects of introducing single-dose or two-dose human papillomavirus vaccination in India.
M de Carvalho T; Man I; Georges D; Saraswati LR; Bhandari P; Kataria I; Siddiqui M; Muwonge R; Lucas E; Sankaranarayanan R; Basu P; Berkhof J; Bogaards JA; Baussano I
BMJ Glob Health; 2023 Nov; 8(11):. PubMed ID: 37931940
[TBL] [Abstract][Full Text] [Related]
8. Current Status of Human Papillomavirus Infection and Introduction of Vaccination to the National Immunization Program in Korea: an Overview.
Kim MA; Han GH; Kim JH; Seo K
J Korean Med Sci; 2018 Dec; 33(52):e331. PubMed ID: 30584412
[TBL] [Abstract][Full Text] [Related]
9. Evolution of Public Health Human Papillomavirus Immunization Programs in Canada.
Goyette A; Yen GP; Racovitan V; Bhangu P; Kothari S; Franco EL
Curr Oncol; 2021 Feb; 28(1):991-1007. PubMed ID: 33617515
[No Abstract] [Full Text] [Related]
10. Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium.
Simoens S; Bento-Abreu A; Merckx B; Joubert S; Vermeersch S; Pavelyev A; Varga S; Morais E
Front Pharmacol; 2021; 12():628434. PubMed ID: 33912045
[No Abstract] [Full Text] [Related]
11. Modeling the Health Impact and Cost-Effectiveness of a Combined Schoolgirl HPV Vaccination and Cervical Cancer Screening Program in Guangdong Province, China.
Huang Y; Zhang D; Yin L; Zhao J; Li Z; Lu J; Zhang X; Wu C; Wu W
Children (Basel); 2024 Jan; 11(1):. PubMed ID: 38255416
[TBL] [Abstract][Full Text] [Related]
12. Opportunities and challenges for human papillomavirus vaccination in China.
Zhao C; Zhao Y; Li J; Li M; Shi Y; Wei L
Hum Vaccin Immunother; 2024 Dec; 20(1):2329450. PubMed ID: 38575524
[TBL] [Abstract][Full Text] [Related]
13. Costs of delivering human papillomavirus vaccination using a one- or two-dose strategy in Tanzania.
Hsiao A; Struckmann V; Stephani V; Mmbando D; Changalucha J; Baisley K; Levin A; Morgan W; Hutubessy R; Watson-Jones D; Whitworth H; Quentin W
Vaccine; 2023 Jan; 41(2):372-379. PubMed ID: 36460537
[TBL] [Abstract][Full Text] [Related]
14. Cancer burden attributable to human papillomavirus infection by sex, cancer site, age, and geographical area in China.
Duan R; Qiao Y; Clifford G; Zhao F
Cancer Med; 2020 Jan; 9(1):374-384. PubMed ID: 31714036
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of single-dose or 2-dose of bivalent, quadrivalent, or nonavalent HPV vaccine in a low/middle-income country setting.
Termrungruanglert W; Khemapech N; Vasuratna A; Havanond P; Tantitamit T
J Gynecol Oncol; 2024 Apr; ():. PubMed ID: 38670561
[TBL] [Abstract][Full Text] [Related]
16. Barriers and facilitators of HPV vaccination in sub-saharan Africa: a systematic review.
Kutz JM; Rausche P; Gheit T; Puradiredja DI; Fusco D
BMC Public Health; 2023 May; 23(1):974. PubMed ID: 37237329
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus vaccination for boys.
Quinn S; Goldman RD
Can Fam Physician; 2015 Jan; 61(1):43-6. PubMed ID: 25756144
[TBL] [Abstract][Full Text] [Related]
18. Assessing the value of human papillomavirus vaccination in Gavi-eligible low-income and middle-income countries.
Ochalek J; Abbas K; Claxton K; Jit M; Lomas J
BMJ Glob Health; 2020 Oct; 5(10):. PubMed ID: 33082132
[TBL] [Abstract][Full Text] [Related]
19. Modeling the cost-effectiveness of maternal acellular pertussis immunization (aP) in different socioeconomic settings: A dynamic transmission model of pertussis in three Brazilian states.
Luz PM; Struchiner CJ; Kim SY; Minamisava R; Andrade ALS; Sanderson C; Russell LB; Toscano CM
Vaccine; 2021 Jan; 39(1):125-136. PubMed ID: 33303180
[TBL] [Abstract][Full Text] [Related]
20. Health impact and cost-effectiveness of expanding routine immunization coverage in India through Intensified Mission Indradhanush.
Clarke-Deelder E; Suharlim C; Chatterjee S; Portnoy A; Brenzel L; Ray A; Cohen J; Menzies NA; Resch SC
Health Policy Plan; 2024 Apr; ():. PubMed ID: 38590052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
